Paul Tudor Jones Biocryst Pharmaceuticals Inc Transaction History
Tudor Investment Corp Et Al
- $29 Billion
- Q1 2025
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 105,042 shares of BCRX stock, worth $1.06 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
105,042
Previous 99,450
5.62%
Holding current value
$1.06 Million
Previous $747,000
5.35%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding BCRX
# of Institutions
292Shares Held
177MCall Options Held
721KPut Options Held
489K-
Vanguard Group Inc Valley Forge, PA21.7MShares$218 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$201 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.93MShares$89.9 Million5.64% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.7MShares$87.6 Million1.06% of portfolio
-
State Street Corp Boston, MA7.81MShares$78.7 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.87B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...